Sep 20, 2023
Press releases
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
Evaxion announced a collaboration with Afrigen Biologics (Afrigen)
Sep 18, 2023
Press releases
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
Evaxion announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen.
Sep 11, 2023
Press releases
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDEN.
Aug 29, 2023
Press releases
Evaxion announces Executive Management Changes to strengthen the AI-strategy
Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years.
Aug 18, 2023
Press releases
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
Evaxion today provided a business update and announced its second quarter 2023 financial results.
Aug 2, 2023
Press releases
Evaxion announces financing commitments totaling up to USD 20 million with Global Growth Holding Limited
Evaxion announced that it has entered into a binding agreement for a financing of up to USD 20 million with Global Growth Holding Limited (GGHL), a leading Dubai-based financial institution specialized in providing flexible equity-linked financings.
Jul 31, 2023
Press releases
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
Evaxion's presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA.
Jun 3, 2023
Press releases
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
Evaxion's EVX-01 met its primary endpoints of safety and tolerability as positive clinical responses were reported.
May 31, 2023
Press releases
Evaxion Announces Business Update and First Quarter 2023 Financial Results
Evaxion today announced its first quarter 2023 financial results and provided a business update.